Pleiotropic effects of type 2 diabetes management strategies on renal risk factors

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 5, 2015, Pages 367-381

  Muskiet, Marcel H A ^a   Tonneijck, Lennart ^a   Smits, Mark M ^a   Kramer, Mark H H ^a   Heerspink, Hiddo J Lambers ^b   van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT;

ALBUMINURIA; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DRUG MECHANISM; DYSLIPIDEMIA; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK REDUCTION;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84928601182     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00030-3     Document Type: Review

References (122)

1. IDF diabetes atlas 2013, International Diabetes Federation, International Diabetes Federation, Brussels, Belgium, (accessed Dec 14, 2014). https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf, 6th edn.
2. Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(suppl 1):S14-S80. American Diabetes Association.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011, 305:2532-2539.
4. KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012, 60:850-886. National Kidney Foundation.
5. Atkins RC, Zimmet P Diabetic kidney disease: act now or pay later. Kidney Int 2010, 77:375-377.
6. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 2014, 37:2864-2883.
7. Mogensen CE, Christensen CK, Vittinghus E The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983, 32(suppl 2):64-78.
8. Porrini E, Mogensen CE, Ruggenenti P, et al, Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 3: 382-91.
9. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232. the UKPDS GROUP.
10. KDIGO clinical practice guideline for evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150. Kidney Disease, the Improving Global Outcomes (KDIGO) Work Groupthe Improving Global Outcomes (KDIGO) Work Group.
11. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2:337-414. KDIGO Blood Pressure Work Group.
12. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013, 3:259-305. Kidney Disease: Improving Global Outcomes.
13. Heerspink HJL, de Zeeuw D The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011, 8:392-402.
14. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
15. Vallon V, Komers R Pathophysiology of the diabetic kidney. Compr Physiol 2011, 1:1175-1232.
16. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012, 172:761-769.
17. Turner R, Holman R, Cull C Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. the UK Prospective Diabetes Study (UKPDS) Group.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
19. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83:517-523. the ADVANCE Collaborative Group.
20. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014, 371:1392-1406. the ADVANCE-ON Collaborative Group.
21. Stevens LA, Greene T, Levey AS Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006, 1:874-884.
22. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014, 64:821-835.
23. Lambers Heerspink HJ, Tighiouart H, Sang Y, et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis 2014, 64:860-866.
24. Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 2014, 64:74-85. the Chronic Kidney Disease Epidemiology Collaboration.
25. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D Microalbuminuria: target for renoprotective therapy PRO. Kidney Int 2014, 86:40-49.
26. Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 2015, 87:649-659.
27. Scheen AJ, Van Gaal LF Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014, 2:911-922.
28. Alicic RZ, Patakoti R, Tuttle KR Direct and indirect effects of obesity on the kidney. Adv Chronic Kidney Dis 2013, 20:121-127.
29. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
30. Rossi MCE, Nicolucci A, Pellegrini F, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008, 23:1278-1284.
31. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010, 25:1173-1183.
32. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014, 2:801-809. Look AHEAD Research Group.
33. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014, 370:2002-2013. the STAMPEDE Investigators.
34. Liu S-C, Tu Y-K, Chien M-N, Chien K-L Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012, 14:810-820.
35. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 3. CD002966.
36. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
37. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013, 159:262-274.
38. Ferrannini G. Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. European Association for the Study of Diabetes Annual Meeting, Vienna; Austria; Sept 15-19, 2014. Oral presentation 3.
39. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
40. Nielsen FS, Rossing P, Bang LE, et al. On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes 1995, 44:783-789.
41. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
42. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840. the ADVANCE Collaborative Group.
43. Gaede P, Pedersen O Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004, 53(suppl 3):S39-S47.
44. Yamout H, Lazich I, Bakris GL Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis 2014, 21:281-286.
45. Upadhyay A, Earley A, Haynes SM, Uhlig K Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154:541-548.
46. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585. the ACCORD Study Group.
47. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of highblood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311:507-520.
48. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 2013, 34:2159-2219.
49. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
50. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
51. Roscioni SS, Heerspink HJL, de Zeeuw D The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2014, 10:77-87.
52. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014, 174:773-785.
53. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013, 382:339-352.
54. Gilbert RE Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int 2014, 86:693-700.
55. Zhang F, Xiang H, Fan Y, et al. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine 2013, 44:648-658.
56. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004, 256:1-14.
57. Qayyum R, Adomaityte J A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006, 8:19-28.
58. Kelly AS, Bank AJ The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 2007, 21:326-334.
59. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014, 27:130-139.
60. Muskiet MH, Smits MM, Morsink LM, Diamant M The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol 2014, 10:88-103.
61. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013, 15:853-862.
62. Brenner BM Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983, 23:647-655.
63. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012, 8:293-300.
64. Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
65. Sasson AN, Cherney DZ Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012, 3:1-6.
66. Zhang PL, Mackenzie HS, Troy JL, Brenner BM Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 1994, 4:1564-1570.
67. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012, 380:1662-1673. the Chronic Kidney Disease Prognosis Consortium.
68. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009, 52:691-697.
69. Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012, 35:2061-2068. the GFR Study Investigators.
70. Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013, 84:164-173. the GFR Study Investigators.
71. Bakris GL, Slataper R, Vicknair N, Sadler R ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994, 8:2-6.
72. Sochett EB, Cherney DZI, Curtis JR, Dekker MG, Scholey JW, Miller JA Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 2006, 17:1703-1709.
73. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011, 80:282-287.
74. Abbate M, Zoja C, Remuzzi G How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006, 17:2974-2984.
75. Birn H, Christensen EI Renal albumin absorption in physiology and pathology. Kidney Int 2006, 69:440-449.
76. Gekle M Renal tubule albumin transport. Annu Rev Physiol 2005, 67:573-594.
77. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995, 26:934-941.
78. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998, 53:1608-1615.
79. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997, 8:1537-1545.
80. Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012, 23:1108-1116. the TESTING Study Group.
81. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown?. J Am Soc Nephrol 1999, 10:2426-2439.
82. de Zeeuw D Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney Int Suppl 2004, 66:S2-S6.
83. Schmieder RE, Mann JFE, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011, 22:1353-1364. the ONTARGET Investigators.
84. Lambers Heerspink HJ, Kröpelin TF, Hoekman J, de Zeeuw D Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 2014, the Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium, published online Nov 24. 10.1681/ASN.2014070688.
85. de Zeeuw D The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013, 369:1960-1962.
86. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54:2206-2211.
87. Ruggenenti P, Flores C, Aros C, et al. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. Diabetes Care 2003, 26:502-509.
88. Schmidt A, Pleiner J, Schaller G, et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int 2002, 61:1788-1793.
89. Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061.
90. von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 2015, 32:343-352.
91. von Scholten BJ, Hansen T, Persson FI, Rossing P. Glucagon-like-peptide (GLP-1): long-term effect on kidney function in patients with type 2 diabetes. American Society of Nephrology Kidney Week; Philadelphia, PA, USA; Nov 11-16, 2014. PUB32350.
92. Mosenzon O, Bhatt DL, Litwak LE, et al. Effects of saxagliptin on renal outcome. European Association for the Study of Diabetes Annual Meeting; Vienna, Austria; Sept 15-19, 2014. 183.
93. Groop P-H, Cooper ME, Perkovic V, Emser A, Woerle H-J, von Eynatten M Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013, 36:3460-3468.
94. Tanaka T, Higashijima Y, Wada T, Nangaku M The potential for renoprotection with incretin-based drugs. Kidney Int 2014, 86:701-711.
95. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014, 129:587-597.
96. Škrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014, 57:2599-2602.
97. Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
98. Kohan DE, Fioretto P, Tang W, List JF Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014, 85:962-971.
99. Cherney DZ, von Eynatten M, Lund SS, Kaspers S, Crowe S, Woerle HJHT. Sodium glucose cotransporter 2 inhibition with empagliflozin reduces microalbuminuria in patients with type 2 diabetes. European Association for the Study of Diabetes Annual Meeting; Vienna, Austria; Sept 15-19. 823.
100. Hung CC, Tsai JC, Kuo HT, Chang JM, Hwang SJ, Chen HC Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud 2013, 10:110-120.
101. Morton J, Zoungas S, Li Q, et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012, 35:2201-2206. the ADVANCE Collaborative Group.
102. Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003, 26:1402-1407. the RENAAL Study.
103. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:251-262.
104. Sandhu S, Wiebe N, Fried LF, Tonelli M Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006, 17:2006-2016.
105. Douglas K, O'Malley PG, Jackson JL Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117-124.
106. De Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015, 3:181-190.
107. Verhulst A, D'Haese PC, De Broe ME Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249-2257.
108. Davis TME, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290.
109. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012, 380:1649-1661. the Chronic Kidney Disease Prognosis Consortium.
110. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328. the ORIGIN Trial Investigators.
111. Buse JB, Tan MH, Prince MJ, Erickson PP The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004, 6:133-156.
112. Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010, 212:223-229.
113. van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab 2013, 15:593-606.
114. Basile JN The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013, 27:280-286.
115. Sinha B, Ghosal S Pioglitazone-do we really need it to manage type 2 diabetes?. Diabetes Metab Syndr 2013, 7:243-246.
116. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011, 7:327-340.
117. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J Therapeutic approaches to diabetic nephropathy-beyond the RAS. Nat Rev Nephrol 2014, 10:325-346.
118. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011, 365:327-336. the BEAM Study Investigators.
119. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013, 369:2492-2503. the BEACON Trial Investigators.
120. Kohan DE, Pollock DM Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013, 76:573-579.
121. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014, 25:1083-1093.
122. Parvanova A, van der Meer IM, Iliev I, et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, 1:19-27. the Daglutril in Diabetic Nephropathy Study Group.